FASEB SRC on Liver Biology: Fundamental Mechanisms and Translational Applications
FASEB SRC on Liver Biology: Fundamental Mechanisms and Translational Applications
批准号:
9121124
负责人:
Robert F. Schwabe
金额:
$3.0万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2017-04-30
关键词:
AmericanAreaAwardBasic ScienceBiologyClinicalClinical TreatmentCollaborationsDiseaseDoctor of PhilosophyEducationEnsureEnvironmentFatty LiverFloridaFosteringFunctional disorderGene ExpressionGoalsHealthHepaticHepatobiliaryHepatologyInflammationInternationalLinkLiverLiver FibrosisLiver RegenerationLiver Stem CellLiver diseasesMalignant neoplasm of liverMedicineMetabolismMinorityOrganogenesisPatient CarePostdoctoral FellowRegenerative MedicineRegulationResearchResearch PersonnelScienceSocietiesStagingStressTranslational ResearchTranslationsUnderrepresented MinorityWomanabstractingcareerinnovationliver injuryliver metabolismmedical specialtiesmeetingsminority investigatorminority scientistnovelposterspreferenceprogramspublic health relevancesymposiumtumor metabolism
中文摘要
描述(由申请人提供):
目前的申请寻求部分支持美国实验生物学学会联合会(FASE B)关于“肝脏生物学:基本机制和翻译应用”的科学研究会议。在过去的20年里,这个会议每两年举行一次,现在被公认为世界上最重要的会议,涵盖了涉及肝脏的基础科学研究的方方面面。大会将于2016年6月26日至7月1日在佛罗里达州西棕榈滩举行。会议的主要目标是:i)整合肝脏生物学不同领域提供的研究进展,以促进国内和国际规模的新的合作项目;ii)鼓励初级和早期研究人员、女性和少数群体科学家从事肝脏研究,以确保肝脏疾病和生物学的研究保持活力;iii)通过基础和临床研究人员的互动,加速将肝脏生物学的基本进展转化为新的临床治疗方法。这些目标将通过具体的方案战略来实现。该计划分为九个主要环节,包括45位受邀演讲者的演讲。此外,这些会议将容纳多个简短的“最新”演讲,这些演讲将被选为代表肝脏研究中最重要和最及时的研究进展。初级调查员、少数民族调查员和女性调查员将获得优先考虑。该项目还提供一对一对话的海报和专家会议,以及在整个逗留期间演讲者和与会者之间进行非正式但亲密的科学交流的几个额外机会。虽然会议将保持涵盖广泛的基础科学和翻译主题的传统-包括肝脏器官发生、肝胆的调节
在健康和疾病、肝再生、肝损伤和纤维化、肝干细胞和再生医学中的基因表达-由于它们的相关性越来越大,将特别关注肝脏代谢和脂肪肝以及肝癌。对于所有主题,重点是最新和最新发现的翻译应用。总而言之,该计划整合了肝脏健康和疾病的基本和应用方面最相关和最及时的主题,以促进科学交流、传播、教育和合作,并将其转化为患者护理。
英文摘要
DESCRIPTION (provided by applicant):
The current application seeks partial support for the Federation of American Societies for Experimental Biology (FASEB) Science Research Conference on "Liver Biology: Fundamental Mechanisms and Translational Applications". For the past 20 years, this meeting has been held biennially and is now recognized as the world's premier conference covering all aspects of basic science research involving the liver. The conference will be held from June 26-July 1, 2016, in West Palm Beach, Florida. The main goals of the conference are to i) integrate the research advances offered by disparate areas of liver biology in order to foster new collaborative projects on both national and international scale, ii) encourage junior and early stage investigators, women and minority scientists to pursue liver research to ensure that the study of hepatic disease and biology remains vigorous and iii) accelerate translation of fundamental advances in liver biology into novel clinical treatments through the interactions of basic and clinical researchers. These goals will be achieved through specific programmatic strategies. The program is divided into nine major sessions and includes presentations from forty-five invited speakers. In addition, these sessions will accommodate multiple short 'late-breaking' talks that will be chosen to represent the most significant and timely research advances in liver research. Preference will be given to junior, minority and women investigators. The program also provides poster and "meet-the-expert" sessions for one-on- one dialogue and several additional opportunities for informal, yet intimate scientific exchange among speakers and attendees throughout the stay. While the conference will keep the tradition of covering a wide range of basic science and translational topics - including liver organogenesis, regulation of hepatobiliary
gene expression in health and disease, liver regeneration, liver injury and fibrosis, liver stem cells and regenerative medicine - there will be particular focus on hepatic metabolisms and fatty liver as well as liver cancer due to their growing relevance. For all topics, emphasis is given to translational application of recent and current discoveries. In summary, the program integrates the most relevant and timely topics in basic and applied aspects of liver health and disease to promote scientific exchange, dissemination, education and collaboration and translation to patient care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Columbia University Digestive and Liver Disease Research Center
-
批准号:10612948
-
项目类别:
-
资助金额:$121.89万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
The Columbia University Digestive and Liver Disease Research Center
-
批准号:10443133
-
项目类别:
-
资助金额:$122.99万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
The Administrative Core
-
批准号:10443134
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
The Administrative Core
-
批准号:10612949
-
项目类别:
-
资助金额:$24.62万
-
财政年份:2022
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10278434
-
项目类别:
-
资助金额:$53.5万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Protective and fibrosis-independent functions of hepatic stellate cells
-
批准号:10597076
-
项目类别:
-
资助金额:$51.8万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Protective and fibrosis-independent functions of hepatic stellate cells
-
批准号:10378664
-
项目类别:
-
资助金额:$53.22万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10454375
-
项目类别:
-
资助金额:$51.51万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
-
批准号:10654714
-
项目类别:
-
资助金额:$50.19万
-
财政年份:2021
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10224799
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:9917105
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10453767
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
DAMPs and Their Receptors Link Hepatocyte Death to HSC Activation and Liver Fibrosis
-
批准号:10021026
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2019
-
负责人:Robert F. Schwabe
-
依托单位:
TAZ and YAP in Non-Alcoholic Steatohepatitis and its Complications
-
批准号:9473156
-
项目类别:
-
资助金额:$66.41万
-
财政年份:2018
-
负责人:Robert F. Schwabe
-
依托单位:
HMGB1 as Link Between Hepatocellular Injury and HCC
-
批准号:9888333
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2016
-
负责人:Robert F. Schwabe
-
依托单位:
HMGB1 as Link Between Hepatocellular Injury and HCC
-
批准号:9258403
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2016
-
负责人:Robert F. Schwabe
-
依托单位:
Hepatic Stellate Cells and Liver Cancer
-
批准号:8801797
-
项目类别:
-
资助金额:$37.02万
-
财政年份:2015
-
负责人:Robert F. Schwabe
-
依托单位:
Hepatic Stellate Cells and Liver Cancer
-
批准号:9003035
-
项目类别:
-
资助金额:$35.83万
-
财政年份:2015
-
负责人:Robert F. Schwabe
-
依托单位:
Promotion of Hepatocellular Carcinoma by Myofibroblasts
-
批准号:8256908
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2011
-
负责人:Robert F. Schwabe
-
依托单位:
Promotion of Hepatocellular Carcinoma by Myofibroblasts
-
批准号:8555377
-
项目类别:
-
资助金额:$18.03万
-
财政年份:2011
-
负责人:Robert F. Schwabe
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: